ATE175354T1 - Verbesserte, gefriergetrocknete ifosfamid- zusammensetzungen - Google Patents

Verbesserte, gefriergetrocknete ifosfamid- zusammensetzungen

Info

Publication number
ATE175354T1
ATE175354T1 AT92118093T AT92118093T ATE175354T1 AT E175354 T1 ATE175354 T1 AT E175354T1 AT 92118093 T AT92118093 T AT 92118093T AT 92118093 T AT92118093 T AT 92118093T AT E175354 T1 ATE175354 T1 AT E175354T1
Authority
AT
Austria
Prior art keywords
dried
improved freeze
ifosfamide
ifosfamide compositions
compositions
Prior art date
Application number
AT92118093T
Other languages
English (en)
Inventor
Robert Lee Alexander
Robert Joseph Behme
Joseph Arthur Scott
Dana Brooke
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE175354T1 publication Critical patent/ATE175354T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92118093T 1991-10-23 1992-10-22 Verbesserte, gefriergetrocknete ifosfamid- zusammensetzungen ATE175354T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/781,436 US5227373A (en) 1991-10-23 1991-10-23 Lyophilized ifosfamide compositions

Publications (1)

Publication Number Publication Date
ATE175354T1 true ATE175354T1 (de) 1999-01-15

Family

ID=25122737

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92118093T ATE175354T1 (de) 1991-10-23 1992-10-22 Verbesserte, gefriergetrocknete ifosfamid- zusammensetzungen

Country Status (24)

Country Link
US (1) US5227373A (de)
EP (1) EP0538858B1 (de)
JP (1) JP3576180B2 (de)
KR (1) KR100247161B1 (de)
CN (1) CN1046202C (de)
AT (1) ATE175354T1 (de)
AU (1) AU658011B2 (de)
CA (1) CA2081061A1 (de)
CZ (1) CZ282445B6 (de)
DE (1) DE69228105T2 (de)
DK (1) DK0538858T3 (de)
EG (1) EG20114A (de)
ES (1) ES2125880T3 (de)
FI (1) FI107701B (de)
GR (1) GR3029835T3 (de)
HU (2) HU221428B (de)
IL (1) IL103496A (de)
MX (1) MX9206105A (de)
MY (1) MY109794A (de)
NZ (1) NZ244816A (de)
RU (1) RU2106138C1 (de)
SK (1) SK279869B6 (de)
TW (1) TW217987B (de)
ZA (1) ZA928104B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
DE19733305A1 (de) * 1997-08-01 1999-02-04 Asta Medica Ag Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin
AU1555099A (en) * 1997-10-13 1999-05-03 Stada Arzneimittel A.G. Liquid presentations of oxazaphosphorine-containing pharmaceutical products
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
CA2476494C (en) 2002-02-22 2010-04-27 Schering Corporation Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
WO2004022699A2 (en) * 2002-09-05 2004-03-18 Bharat Serums And Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna
BR0316968A (pt) * 2002-12-02 2005-10-25 Bharat Serums & Vaccines Ltd Composições estáveis, claras, aquosas de ifosfamida para administração parenteral que apresentam pouca toxicidade; processo para a preparação de composições de ifosfamida; e composições de ifosfamida e um processo para a preparação das mesmas
US7199111B2 (en) * 2002-12-02 2007-04-03 Bharat Serums & Vaccines Ltd. Aqueous ifosfamide compositions for parenteral administration and a process for their preparations
SI1667655T1 (sl) * 2003-10-01 2011-10-28 Baxter Int Nova uporaba, farmacevtski pripravki, kot tudi postopek za njihovo proizvodnjo
TW200621240A (en) * 2004-11-05 2006-07-01 Salmedix Inc Cancer treatments
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1973406B1 (de) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation Abgabekonstituens für probiotische bakterien umfassend eine trockene matrix aus polysacchariden, sacchariden und polyolen in glasform
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
MX2009003197A (es) * 2006-09-29 2009-05-08 Infa Sa Sistema de embalaje para composiciones farmaceuticas y equipo para administracion intravenosa.
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
US20100210700A1 (en) * 2007-05-08 2010-08-19 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2326306A1 (de) * 2008-09-25 2011-06-01 Cephalon, Inc. Flüssige formulierungen von bendamustin
CA2749101A1 (en) * 2009-01-15 2010-07-22 Cephalon, Inc. Novel forms of bendamustine free base
CA2986751A1 (en) 2009-03-27 2010-09-30 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
ES2643148T3 (es) * 2009-05-26 2017-11-21 Advanced Bionutrition Corporation Composición en polvo seco estable que comprende microorganismos biológicamente activos y/o materiales bioactivos y métodos de producción
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
BR112012018839B1 (pt) 2010-01-28 2020-04-14 Advanced Bionutrition Corp composição vítrea seca compreendendo um material bioativo
BR112013003244B1 (pt) 2010-08-13 2018-07-17 Advanced Bionutrition Corp composição seca estabilizante para material biológico, seu método de preparação, e formulação de carreamento oral
ES2750749T3 (es) * 2014-01-06 2020-03-27 Auxin Surgery Sa Composiciones de Mesna liofilizadas
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
PT3328215T (pt) 2015-07-29 2021-08-03 Advanced Bionutrition Corp Composições probióticas estáveis secas para utilizações dietéticas especiais
JP6706988B2 (ja) * 2016-07-20 2020-06-10 日本化薬株式会社 ボルテゾミブを含有する医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
ZA851062B (en) * 1984-03-01 1985-11-27 Asta Werke Ag Chem Fab Salts of oxazaphosphorine derivatives and process for their production
EP0254902B1 (de) * 1986-07-11 1991-08-28 ASTA Pharma Aktiengesellschaft Lösungen von Oxazaphosphorinen mit verbesserter Stabilität und Verfahren zu deren Herstellung
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
DE3862595D1 (de) * 1987-03-06 1991-06-06 Asta Pharma Ag Verfahren zur herstellung von ifosfamid mit verbesserten eigenschaften.
ES2040394T3 (es) * 1988-03-19 1993-10-16 Asta Medica Aktiengesellschaft Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide

Also Published As

Publication number Publication date
ZA928104B (en) 1993-07-20
IL103496A (en) 1996-07-23
HU211293A9 (en) 1995-11-28
JP3576180B2 (ja) 2004-10-13
KR100247161B1 (ko) 2000-04-01
DE69228105D1 (de) 1999-02-18
CN1073358A (zh) 1993-06-23
CN1046202C (zh) 1999-11-10
TW217987B (de) 1993-12-21
HUT69384A (en) 1995-09-28
EP0538858A1 (de) 1993-04-28
MX9206105A (es) 1993-04-01
HU9203306D0 (en) 1992-12-28
FI924797A (fi) 1993-04-24
NZ244816A (en) 1994-06-27
CZ282445B6 (cs) 1997-07-16
AU658011B2 (en) 1995-03-30
RU2106138C1 (ru) 1998-03-10
AU2716692A (en) 1993-04-29
JPH05246856A (ja) 1993-09-24
KR930007453A (ko) 1993-05-20
EG20114A (en) 1997-07-31
ES2125880T3 (es) 1999-03-16
FI107701B (fi) 2001-09-28
HU221428B (en) 2002-10-28
SK279869B6 (sk) 1999-04-13
GR3029835T3 (en) 1999-06-30
FI924797A0 (fi) 1992-10-22
IL103496A0 (en) 1993-03-15
SK317692A3 (en) 1995-11-08
MY109794A (en) 1997-06-30
DE69228105T2 (de) 1999-08-26
US5227373A (en) 1993-07-13
EP0538858B1 (de) 1999-01-07
CA2081061A1 (en) 1993-04-24
DK0538858T3 (da) 1999-08-30
CZ317692A3 (en) 1993-09-15

Similar Documents

Publication Publication Date Title
ATE175354T1 (de) Verbesserte, gefriergetrocknete ifosfamid- zusammensetzungen
RU92004463A (ru) Усовершенствованные лиофилизированные поросерамидные композиции
EP0483329A4 (en) Novel lyophilized and reconstituted cell compositions
NO2004004I1 (no) Bortezomib eller en farmasøytisk akseptabel ester derav, eventuelt i form av et farmasøytisk akseptabelt salt derav
PT871476E (pt) Composicao seca de factor sanguineo compreendendo trealose
DE3883035D1 (de) Saponinkomplexe mit phospholipiden und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
DE68906458D1 (de) Lyophilisation von erythrozyten und dafuer brauchbare mittel.
FI891283A0 (fi) Ifosfamid-mesna-lyofilisat och foerfarande foer dess framstaellning.
NO924492D0 (no) Inklusjonsforbindelser av nimesulide med cyklodekstriner
PT94344A (pt) Processo para a preparacao de uma composicao estavel seca por congelacao a base de esteres/eteres de poli-hematoporfirina
DE3884663D1 (de) Gefriergetrockneter, stabiler, lebendiger Herpesvirus-Impfstoff.
ES2130359T3 (es) Esteres neoalquil alquiliden-2,2'-bisfenil y bifenil fosfito.
TH2730EX (th) ลูกล้อสำหรับเฟอร์นิเจอร์
TH2729EX (th) ลูกล้อสำหรับเฟอร์นิเจอร์
MX9634A (es) Procedimiento para la preparacion de un activador plasminogeno hibrido, producto obtenido, mutante del mismo, vector hibrido para modificar adn y composicion farmaceutica que incluye el activador de plasminogeno.
TH1912EX (th) ตัวยืด
SE8000499L (sv) Milgasugn, i synnerhet for brenning av treflis och torv
ES1007258U (es) Caja automontable perfeccionada.
TH1912S (th) ตัวยืด

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee